...
首页> 外文期刊>Vaccine >Lessons learned from clinical trials evaluating pneumococcal conjugate vaccine efficacy against pneumonia and invasive disease.
【24h】

Lessons learned from clinical trials evaluating pneumococcal conjugate vaccine efficacy against pneumonia and invasive disease.

机译:从评估肺炎球菌结合疫苗抗肺炎和侵袭性疾病功效的临床试验中学到的经验教训。

获取原文
获取原文并翻译 | 示例
           

摘要

This article discusses lessons learned from clinical trials with pneumococcal conjugate vaccines (PCVs). A review of major clinical trials investigating PCV efficacy, this article provides the context to explore challenges associated with studying pneumococcal pneumonia and vaccine efficacy, particularly related to non-bacteremic disease, serotypes, and radiograph interpretation. Throughout these clinical trials, improving the pneumonia diagnosis specificity increased vaccine efficacy estimates. Additional analysis suggests this improvement may come at a cost of detecting much less of the disease burden. The article concludes with a discussion of the potential value of C-reactive protein as an adjunctive marker in measuring PCV efficacy against non-bacteremic pneumococcal pneumonia.
机译:本文讨论了肺炎球菌结合疫苗(PCV)从临床试验中学到的经验教训。本文综述了研究PCV功效的主要临床试验,为探索与研究肺炎球菌性肺炎和疫苗功效相关的挑战提供了背景,特别是与非细菌性疾病,血清型和X线片解释有关的挑战。在整个这些临床试验中,改善肺炎的诊断特异性可提高疫苗功效的估计值。进一步的分析表明,这种改善可能以检测到更少的疾病负担为代价。文章最后讨论了C反应蛋白作为辅助标记物在测量PCV对非细菌性肺炎球菌性肺炎的疗效中的潜在价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号